Kilitch Drugs (India) share news and announcements
NSE: KILITCHBSE: 524500Pharmaceuticals & BiotechnologySmall Cap
Last close ₹202.24up ₹0.13 (0.06%)BSE ₹203.50
Share price at the NSE close on 23 Oct 2026. Previous close ₹202.11.
52-week range of traded prices to 23 Oct 2026
₹117.25Low, 30 Mar 2026₹267.90High, 7 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹707 Cr1,776th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 23.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 May 2026
- 2.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 12.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 8.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 May 2026
- 0.32
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,44,52347.0% delivered
Kilitch Drugs (India) share news and announcements
492 announcements, routine notices left out, newest first. Page 4 of 10.
Apr 2022
11 Apr · Legal
The exchange asked on 8 Apr 2022
Mar 2022
3 Mar · General updates
3 Mar · Disclosure of other UPSI/material event
Feb 2022
Jan 2022
24 Jan · Board meeting
Dec 2021
20 Dec · Board meeting
Nov 2021
12 Nov · Board meeting
Oct 2021
13 Oct · Board meeting
Sep 2021
Aug 2021
20 Aug · Legal
Exchange has sought clarification from Kilitch Drugs (India) Limited with respect to announcement dated 13-Aug-2021, regarding Appointment of Statutory Auditor. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment).The response of the Company is awaited.13 Aug · Board meeting
Jul 2021
23 Jul · Legal
Significant movement in price has been observed in Kilitch Drugs (India) Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Jun 2021
22 Jun · Board meeting
Apr 2021
30 Apr · Disclosure
Mar 2021
Feb 2021
26 Feb · Updates